{"disease":{"id":"hrd","name":"hrd"},"drugs":{"marketed":[],"pipeline":[{"drug_id":"olaparib-oral-product","indication_name":"BRCA1/2-mutated and HRD-positive advanced solid tumors","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib Oral Product","company_name":"Duke University","drug_phase":"discontinued","molecular_target":"PARP-1 and PARP-2 (poly-ADP-ribose polymerase enzymes)","drug_class":"PARP inhibitor (DNA repair inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits poly-ADP-ribose polymerase (PARP) enzymes to impair DNA repair in cancer cells with BRCA mutations or homologous recombination deficiency."}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT06622798","title":"Exploratory Study on the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients","phase":"","overall_status":"RECRUITING","enrollment_count":470,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT04826341","title":"A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06614751","title":"A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":112,"lead_sponsor_name":"Danatlas Pharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT07156253","title":"Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd","has_results":false},{"nct_id":"NCT03415659","title":"Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":85,"lead_sponsor_name":"Hubei Biological Medicine Industrial Technology Institute Co., Ltd.","has_results":false},{"nct_id":"NCT05656131","title":"Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":80,"lead_sponsor_name":"wang shusen","has_results":false},{"nct_id":"NCT06254066","title":"Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT05085626","title":"Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT03712930","title":"Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT07455071","title":"A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":9,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT06065059","title":"Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Tango Therapeutics, Inc.","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}